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This paper reports a new technology platform that 
advantageously combines organic solvent nanofiltration (a newly 
emerging technology capable of molecular separations in organic 
solvents) with solution phase peptide synthesis - Membrane 
Enhanced Peptide Synthesis (MEPS). 10 
In the last decade the market for peptide based 
pharmaceuticals has been growing rapidly: as of 2005 an 
estimated 40 peptide-based pharmaceutical products were for 
sale, with approximately 270 more in different phases of 
clinical trials 1. Large-scale peptide manufacture is essential 15 
to bring these drugs to market. Solid-phase peptide synthesis 
(SPPS) is the most widely used technology, since it neatly 
solves the critical purification problems encountered at each 
stage in solution phase synthesis. However it faces serious 
challenges including mass transfer, steric hindrance, and resin 20 
handling 2,3,4. The concept of membrane separation coupled to 
solution phase synthesis offers major advantages over SPPS 
by combining the advantages of “classical” solution phase 
synthesis with the ease of purification of the solid phase 
method 2. Compared to SPPS, reactions in solution phase 25 
provide faster rates, and are less affected by steric hindrance 
due to peptide folding, or reactions within confined space 
which result in transpeptidation, and are not limited by 
intraparticle diffusional mass transfer phenomena 3,4. This 
enables reduction in the large reactant excesses, in some cases 30 
of up-to 5-fold5,6, that are employed in SPPS to compensate 
for mass transfer limitations.  Solution phase reactions are 
also easier to scale-up due to the absence of swelling effects 
and cake formation within solid resins, which require more 
complex reactor design. Prior applications of membrane 35 
separation in peptide chemistry are restricted to re-
concentration of peptides 7, amino acid recovery 8,9, and a 
single report on membrane separation for purification between 
reaction cycles during peptide synthesis 2,10. In the latter case, 
peptides built on poly(ethylene glycol) (PEG) were separated 40 
from impurities by ultrafiltration. However, due to a lack of 
organic solvent-compatible membranes, this required 
evaporation of organic solvent after each coupling and each 
deprotection step, neutralisation after deprotection, and uptake 
in water prior to ultrafiltration. Water was then removed by 45 
evaporation and/or azeotropic distillation before re-dissolving 
the PEG-peptide into organic solvent for the next coupling 
step. This complex process limited the synthesis to volatile 
organic solvents, and the lengthy solvent switching system 
made the separation process unsuitable for large-scale 50 
production. Molecular separation in organic solvents via 
nanofiltration (Organic Solvent Nanofiltration – OSN) is an 
emerging technology 11, which should be an ideal separation 
method for in-cycle purification during peptide synthesis. 
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Figure 1: Schematic representation of membrane enhanced peptide 
synthesis (MEPS).  Peptide chain assembly was performed following this 
scheme using the apparatus presented in Figure 4. 
. Here we report for the first time Membrane Enhanced 
Peptide Synthesis (MEPS), a new technology platform that 60 
advantageously combines OSN with solution phase peptide 
synthesis. 
 The MEPS concept is illustrated in Figure 1. Peptide chain 
assembly occurs via: 1) amide coupling; 2) a washing step for 
removal of excess reagents via constant volume diafiltration; 65 
3) deprotection; 4) a washing step for removal of deprotection 
by-products and excess reagents again via diafiltration. The 
cycle is repeated as many times as necessary, adding a further 
amino acid each cycle, until the desired peptide sequence is 
obtained. In contrast to the previously reported studies 2,10 70 
washing is carried out immediately after the coupling and 
deprotection steps using the reaction solvent, and does not 
require any solvent exchanges. 
 The peptide is assembled on a soluble polymeric support, 
methoxy-amino-PEG with molecular weight (MW) 5,000 75 
g.mol-1 (MeO-PEG-NH2), to increase retention by the 
membrane 3. Since PEGylated peptides have received much 
recent attention due to their enhanced therapeutic and 
pharmacokinetic potential 12-14, in some cases a bioactive 
peptide made by MEPS might also be used directly without 80 
cleavage from PEG. 
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 Fmoc (9-fluorenylmethoxycarbonyl) peptide synthesis 
chemistry was chosen due to its widespread application and 
mild deprotection conditions (piperidine/DMF). 
Hydroxymethylphenylacetic acid (HMPA) was used as linker 
to attach the first amino acid in the peptide sequence to the 5 
MeO-PEG-NH2 enabling facile cleavage of the final peptide 
via acidolysis. Peptide coupling proceeds optimally in polar 
aprotic solvents such as dimethylformamide (DMF) or N-
methyl pyrrolidinone (NMP), and DMF was used in both 
reaction and diafiltration steps. The use of these solvents in 10 
combination with OSN membranes has only recently become 
possible with the development of membranes 15 which possess 
good stability in these aprotic solvents and make this 
approach viable. 
 The most important consideration for successful realisation 15 
of this approach was the choice of membrane. This must 
possess excellent long term stability in the reaction solvent 
(DMF) and high selectivity between MeO-PEG-peptide, and 
side reaction products and excess reagents, including 
unreacted amino acids, activators and deprotection reagents. 20 
Membrane performance should not be affected by frequent 
switching of the reaction media between DMF solution in the 
coupling step and 20% piperidine/DMF solution in the 
deprotection step. 
 After screening a range of commercial and developmental 25 
membranes we identified a ceramic OSN membrane that met 
these requirements: the Inopor ZrO2 coated membrane with 
3nm pore size and hydrophobic surface modification 
(Innocermic, Germany). Based on the membrane 
characterisation data it was estimated that 10-12 solvent wash 30 
volumes should be sufficient for removal of all excess 
reagents from around 1.0 to less than 0.01 equivalents. 
 To prove the MEPS concept we started by producing a 
model peptide H-Tyr-Ala-Tyr-Ala-Tyr-OH. This was chosen 
as it includes one of the largest protected amino acids Fmoc-35 
Tyr(tBu)-OH, and one of the smallest hydrophobic amino 
acids, Fmoc-Ala-OH, thus providing information on the 
performance of the MEPS process with respect to different 
molecular sizes and properties of amino acids. PyBOP was 
chosen for the coupling reaction as it is one of the largest of 40 
the commercial activators available, and its successful 
removal presents a challenge for the MEPS process. DIC was 
used for the esterification linking the first amino acid onto 
MeO-PEG-HMPA. Thus the synthesis also provided insight 
into the behaviour of the post-reaction species derived from 45 
both activators during diafiltration. Finally, this first 
experiment also sought to establish membrane stability at high 
concentrations of organic base (piperidine) during the 
deprotection step (see Table S1, Supporting Information). 
 The model peptide produced contained no peptide by-50 
products as confirmed by RP-HPLC and MALDI-TOF 
analysis. This absence of any detectable peptide impurities 
indicates that membrane purification is efficient at removing 
un-reacted protected amino acids throughout the synthesis. 
Our calculations suggested that traces of impurities would still 55 
remain in the system after each purification step even after 10 
volumes of washing solvent, but this did not affect the final 
peptide purity. Apparently the level of impurities that can be 
 
Figure 2: HPLC chromatograms of peptide TP-5 produced by MEPS and 60 
SPPS processes, and TP-5 standard purchased from Sigma-Aldrich (UK). 
The target TP-5 peptide was eluted at 10.3 minutes. Both syntheses 
(MEPS and SPPS) were performed under the same reaction conditions of 
2 equivalents of reagents per 1 equivalent peptide, and single reaction 
cycles. Peptide purity was determined as a ratio between the target 65 
peptide TP-5 peak area and the total area of the peaks corresponding to 
peptide sequences in the solution. The purity of TP-5 produced by MEPS 
was determined as ~94% (two impurities eluted at 10.0 minutes and 10.4 
minutes) while TP-5 produced by SPPS was ~77% pure (one impurity 
eluted at 10.5 minutes). The large peaks eluted between 19 - 23 minutes 70 
were PEGylated wastes such as MeO-PEG-HMPA and the peak eluted at 
13 minutes was not of peptide origin as confirmed by MALDI-TOF 
analysis and were not taken into account for the purity calculations.  
tolerated in the system without provoking side reactions is 
higher than anticipated, and so there is potential to reduce the 75 
washing volume. 
 Encouraged by this first success, Thymopentin (H-Arg-Lys-
Asp-Val-Tyr-OH) was synthesized as a second demonstration 
of the MEPS process. Thymopentin (TP-5) is a derivative of 
the naturally occurring hormone thymopoietin, with potential 80 
for the treatment of rheumatoid arthritis, AIDS and other 
primary immunodeficiencies 16. Besides being a potential 
active pharmaceutical, this peptide includes a range of amino 
acids from aromatic (Tyr), acidic (Asp) and basic (Lys and 
Arg) to hydrophobic (Val). It also contains the largest 85 
Fmoc/Boc protected amino acid (Fmoc-Arg(Boc)2, M.W. 597 
g.mol-1, and so this synthesis represents a significant further 
challenge for MEPS. RP-HPLC analyses of TP-5 produced by 
both MEPS and SPPS are illustrated in Figure 2. 
 The purity of the MEPS product (as a percentage of total 90 
(TP-5 plus peptidic by-products)) was estimated at 94%. 
MALDI-TOF analysis (Figure 3) confirmed the target product 
molecular weight of MH+ 680 and identified the two 
impurities as formed by deletion of Asp, MH+ 564, and Lys, 
MH+ 550. TP-5 produced by SPPS under the same reagent 95 
excess (2 equivalents) was only 77% pure and the main 
impurity was identified as deletion of Arg, MH+ 524. This 
result demonstrates the key advantage of liquid phase 
synthesis over SPPS – a higher purity was obtained using the 
same excess of reagents. Typically more equivalents are 100 
needed for SPPS 5. The overall yield of TP-5 produced by the 
MEPS process was estimated to be 92%, with respect to the 
starting MeO-PEG-NH2 material. 
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 For this investigation batch size of 0.9 mmol TP-5 was 
produced which yielded ~0.6 g of product respectively. With 
Figure 3: MALDI-TOF mass spectrum of the different peptides produced 
by MEPS and SPPS TP-5 synthesis and isolated using semi-preparative 
HPLC. Spectrum B) – from the MEPS process and D) – from the SPPS 5 
process correspond to the peak eluted at 10.3 minutes. It was identified as 
TP-5 and showed the target molecular mass, MH+ of 680 Da. Spectrum 
A) and C) – from the MEPS process correspond to the two impurities 
eluted at 10.0 and 10.4 minutes respectively and were identified as 
deletion of Lys, MH+ 550 Da and Asp, MH+ 564 Da. Spectrum E) from 10 
the SPPS process corresponds to the impurity eluted at 10.5 minutes and 
was identified as deletion of Arg, MH+ 524 Da. 
 
Figure 4: Experimental set-up used for peptide chain assembly: Both 
coupling and deprotection reactions were performed in the Reaction 15 
Vessel where mixing was provided via the Circulation Pump. Upon 
completion of each reaction, the system was pressurised to 7 barg using 
nitrogen gas. Fresh DMF solvent was pumped via an HPLC pump from 
the Solvent Reservoir into the system to replace the permeated solvent 
and maintain constant liquid volume within the Reaction Vessel; (a) 20 
Inopor ZrO2 ceramic membrane – front view; (b) SEM image of the 
Inopor ZrO2 ceramic membrane - edge view at magnification 370x. The 
line bar corresponds to 50 μm. 
the current laboratory set-up (Figure 4) > 20 mmol batches of 
peptide can be produced by simply increasing the feed volume 25 
and using identical operating conditions. Further scale-up to 
kilogram or ton scale may be possible by increasing the size 
of the equipment. 
 The MEPS process proposed in this work integrates the 
advantages of performing peptide synthesis in solution with a 30 
direct membrane purification of the post-reaction mixture. 
The process is less constrained by mass-transfer limitations, 
and requires a smaller excess of reagents, than SPPS, yet 
demonstrates excellent purity and yield of the final peptide. 
We anticipate that further optimisation of the separation step 35 
and wash solvent volume will result in solvent savings and 
improved process economics. Thus, we conjecture that the 
MEPS process offers an important alternative technology 
platform for peptide and PEGylated peptide production at 
industrial scale. 40 
 This work was funded by the U.K. Engineering and 
Physical Sciences Research Council (EPSRC) Grant 
NoEP/C50982X/1; The authors would like to acknowledge 
also the financial support from the FP7 IAPP EC Grant 
NoPIAP-GA-2008-218068. 45 
Notes and references 
a Department of Chemical Engineering, Imperial College London, 
London SW7 2AZ, UK. Fax: +44 (0)20 75945629; Tel: +44 (0)20 
75945582; E-mail: a.livingston@imperial.ac.uk 
b Department of Chemistry, Imperial College London, London SW7 2AZ, 50 
UK. E-mail e.tate@imperial.ac.uk 
† Electronic Supplementary Information (ESI) available: Experimental 
Methods and Procedures; Peptide Synthesis; Analysis ; Peptide purity and 
yield. See DOI: 
 55 
1 B. Bray, Nature Review Drug Discovery, 2003, 2, 587 – 593. 
2 E. Bayer, M. Mutter, Nature, 1972, 237, 512 – 513. 
3 E. Bayer, M. Mutter, R. Uhmann, J. Polster, H. Mauser, J. Am. Chem. 
Soc., 1974, 96, 7333-7336. 
4 V. Gut , J. Rudinger  in Peptides 1968, (Eds.: E. Bricas) Amsterdam, 60 
1968, 185-188. 
5 M. Amblard, J. Fehrentz, J. Martinez, G. Subra, Mol. Biotech., 2006, 
33, 239 – 254. 
6 W. Chan, P. White, Fmoc solid phase peptide synthesis: a practical 
approach, Oxford University Press, 2000. 65 
7 T. Tsuru, S. Nakao, S. Kimura, T. Shutou, Sep. Sci. Technol., 1994, 29, 
971 – 984. 
8 S-L. Li, C. Li , Y-S. Lui, X-L. Wang, Z-A. Cao, J. Membr. Sci., 2003, 
222, 191 – 201. 
9 X. Wang, A. Ying, W. Wang, J. Membr. Sci., 2002, 196, 59 – 67. 70 
10 E. Bayer, D. Gillessen, H. Kuenzi, M. Mutter, R. Studer (F. 
Hoffmann-La Roche & Co.), DE-F2047413, 1980. 
11 P. Vandezande,  L.E.M. Gevers, I.F.J. Vankelecom,  Chem. Soc. Rev., 
2008, 37, 365-405. 
12 M. Hamidi, A. Azadi, P. Rafiei, Drug Delivery., 2006, 13, 399 – 409. 75 
13 S.-H. Lee, S. Lee, Y. Youn, D. Na, S. Chae, Y. Byun, K. Lee, 
Bioconjugate Chem., 2005, 16, 377 – 382. 
14 M. Roberts, M. Bentley, J. Harris, Adv. Drug Delivery Rev., 2002, 54, 
459 – 476. 
15 Y. See Toh, F. Lim, A. Livingston, J. Membr. Sci., 2007, 301, 3–10. 80 
16 E. Ochoa, S. Medrano, M. de Carlin, A. Dilonardo, Cell. Mol. 
Neurobiol., 1988, 8, 325 – 331. 
 
Pressurised 
N2 (g) Supply 
Permeate Flow 
Circulation 
Pump 
HPLC Pump 
S
o
lv
en
t R
eserv
o
ir 
Membrane Housing 
R
eactio
n
 V
essel 
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